12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ponesimod: Phase II data

Top-line data from a double-blind, international Phase II trial in 326 patients with moderate to severe chronic plaque psoriasis showed that induction therapy with once-daily 20 and 40 mg oral ponesimod each met the primary endpoint of a greater proportion of patients achieving a PASI 75 response at week 16 vs. placebo (46% and 48.1%, respectively,...

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >